ロード中...
Trastuzumab: updated mechanisms of action and resistance in breast cancer
HER2-postitive breast cancer has the second-poorest prognosis among breast cancer subtypes. One of the most effective targeted therapies for patients with HER2-positive breast cancer is trastuzumab-based. However, primary or acquired resistance to trastuzumab has been a major obstacle in the clinica...
保存先:
| 主要な著者: | , |
|---|---|
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Frontiers Media S.A.
2012-06-01
|
| シリーズ: | Frontiers in Oncology |
| 主題: | |
| オンライン･アクセス: | http://journal.frontiersin.org/Journal/10.3389/fonc.2012.00062/full |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|
ロード中...